Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three-Month Dry Spell For EU PRIME Scheme

Executive Summary

Not one of the applications reviewed by the European Medicines Agency this year for a place on its scheme for drugs for unmet medical needs has made the grade. Meanwhile, the agency recently explained how applicants could improve their chances of getting accepted on the initiative.

You may also be interested in...



Expedited Programs: Overworked Staff & Financial Motives

A shortage of staff and expertise at regulatory agencies as well as tough eligibility criteria can impact expedited programs and their capacity to help deliver quicker access to innovative products.

Solid Tumor CAR-T & AMD Gene Therapy Win EMA PRIME Designations

The first half of 2022 saw a total of seven promising treatments for unmet medical needs make it onto the European Medicines Agency’s priority medicine scheme.

PRIME Dry Spell Over As EMA Says Yes To Pfizer & BioCryst

This year’s first designations under the European Medicines Agency’s priority medicines scheme have gone to a maternal vaccine for an infection in newborns and a treatment for an ultra-rare bone disorder.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel